Abstract
The oral route is the most suitable and physiological delivery route. Oral insulin delivery would minimize the health hazard implied in repeated injection, surpass complications arising from the need for sterile techniques associated with parenteral formulations and provide better glucose homeostasis. However, it is limited by various physiological barriers and still remains a scientific challenge. The desire to deliver insulin by the oral route in a conveniently and effectively way has led to the intense investigation of new delivery systems. Nanodelivery systems have been proposed to enhance the bioavailability of insulin after oral administration. This review article describes the gastrointestinal barriers to oral insulin delivery, including chemical, enzymatic and absorption barriers. The potential transport mechanisms of insulin delivered by nanoparticles across the intestinal epithelium are also addressed. Finally, how nanoparticles characteristics affect insulin pharmacological activity and bioavailability is discussed.
Keywords: Absorption mechanisms, bioavailability, insulin, nanoparticle, oral administration.
Current Pharmaceutical Biotechnology
Title:Intestinal Uptake of Insulin Nanoparticles: Facts or Myths?
Volume: 15 Issue: 7
Author(s): Marlene A. Lopes, Barbara A. Abrahim, Raquel Seica, Francisco Veiga, Carlos R. Rodrigues and Antonio J. Ribeiro
Affiliation:
Keywords: Absorption mechanisms, bioavailability, insulin, nanoparticle, oral administration.
Abstract: The oral route is the most suitable and physiological delivery route. Oral insulin delivery would minimize the health hazard implied in repeated injection, surpass complications arising from the need for sterile techniques associated with parenteral formulations and provide better glucose homeostasis. However, it is limited by various physiological barriers and still remains a scientific challenge. The desire to deliver insulin by the oral route in a conveniently and effectively way has led to the intense investigation of new delivery systems. Nanodelivery systems have been proposed to enhance the bioavailability of insulin after oral administration. This review article describes the gastrointestinal barriers to oral insulin delivery, including chemical, enzymatic and absorption barriers. The potential transport mechanisms of insulin delivered by nanoparticles across the intestinal epithelium are also addressed. Finally, how nanoparticles characteristics affect insulin pharmacological activity and bioavailability is discussed.
Export Options
About this article
Cite this article as:
Lopes A. Marlene, Abrahim A. Barbara, Seica Raquel, Veiga Francisco, Rodrigues R. Carlos and Ribeiro J. Antonio, Intestinal Uptake of Insulin Nanoparticles: Facts or Myths?, Current Pharmaceutical Biotechnology 2014; 15 (7) . https://dx.doi.org/10.2174/1389201015666140915151319
DOI https://dx.doi.org/10.2174/1389201015666140915151319 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Vascular Abnormalities in Essential Hypertension
Current Pharmaceutical Design Islets From Rats and Pigs Transgenic for Photogenic Proteins
Current Diabetes Reviews Eye Disorders in Diabetes: Potential Drug Targets
Infectious Disorders - Drug Targets Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
Current Vascular Pharmacology Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Treatment of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Skin Regeneration: The Possibilities
Recent Patents on Regenerative Medicine Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Vascular Effects of Avocado Seed Glycosides during Diabetes-induced Endothelial Damage
Cardiovascular & Hematological Disorders-Drug Targets